Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 4/20 | 0.54 |
| ▸ | DRD2 | P14416 | 4/20 | 0.54 |
| ▸ | HTR2A | P28223 | 4/20 | 0.54 |
| ▸ | HTR7 | P34969 | 4/20 | 0.54 |
| ▸ | HTR6 | P50406 | 4/20 | 0.54 |
| ▸ | PGK1 | P00558 | 1/20 | 0.53 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.53 |
| ▸ | IP6K1 | Q92551 | 2/20 | 0.52 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.51 |
| ▸ | PAK4 | O96013 | 8/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20281071 | 0.92 | HTR1A (0.62) | HTR1ADRD2HTR2AHTR7HTR6 | |
| SCHEMBL23342409 | 0.88 | PDE10A (0.49) | HTR1ADRD2HTR2AHTR7HTR6 | |
| SCHEMBL30526272 | 0.87 | HTR1A (0.60) | HTR1ADRD2HTR2AHTR7HTR6 | |
| SCHEMBL20267158 | 0.87 | HTR1A (0.60) | HTR1ADRD2HTR2AHTR7HTR6 | |
| SCHEMBL20280920 | 0.83 | HTR1A (0.54) | HTR1ADRD2HTR2AHTR7HTR6 | |
| SCHEMBL20281070 | 0.82 | APP (0.60) | HTR1ADRD2HTR2AHTR7HTR6 | |
| SCHEMBL20267012 | 0.81 | HTT (0.57) | HTR1ADRD2HTR2AHTR7HTR6 | |
| SCHEMBL20281016 | 0.80 | CYP1A2 (0.67) | HTR1ADRD2HTR2AHTR7HTR6 | |
| SCHEMBL20280940 | 0.79 | MEN1 (0.57) | HTR1ADRD2HTR2AHTR7HTR6 | |
| SCHEMBL20280944 | 0.79 | CYP1A2 (0.60) | HTR1ADRD2HTR2AHTR7HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718609-B2 | Heparanase inhibitors and use thereof | Beta Therapeutics Pty Ltd (AU) | 2023-08-08 | — | — | US | disclosed |
| US-11718609-B2 | Heparanase inhibitors and use thereof | Beta Therapeutics Pty Ltd (AU) | 2023-08-08 | — | — | US | disclosed |
| US-20210130338-A1 | Heparanase Inhibitors and Use Thereof | Beta Therapeutics Pty Ltd (AU) | 2021-05-06 | — | — | US | disclosed |
| US-20200093852-A1 | Methods of Treating Ocular Disorders | Beta Therapeutics Pty Ltd (AU) | 2020-03-26 | — | — | US | disclosed |
| WO-2018107200-A1 | HEPARANASE INHIBITORS AND USE THEREOF | Beta Therapeutics Pty Ltd (AU) | 2018-06-21 | — | — | WO | disclosed |
| WO-2018107226-A1 | METHODS OF TREATING OCULAR DISORDERS | Beta Therapeutics Pty. Ltd. (AU) | 2018-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200093852-A1 | Methods of Treating Ocular Disorders | ALDH1A2, HPSE, RB1 | HTR1A 4553/4885DRD2 4882/4885HTR2A 4539/4885 |
| US-20210130338-A1 | Heparanase Inhibitors and Use Thereof | HPSE, HEXD, ENGASE | HTR1A 1542/4885DRD2 4744/4885HTR2A 1332/4885 |
| US-11718609-B2 | Heparanase inhibitors and use thereof | HPSE, HEXD, ENGASE | HTR1A 1542/4885DRD2 4744/4885HTR2A 1332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.